ABSTRACT
Gastroparesis is an important complication of diabetes. Motility disorders are underdiagnosed and can lead to unexplained hypoglycemia. Currently diagnostic options are limited. All established methods harbor certain disadvantages. The 3D-MAGMA system is capable of reliably measuring gastric and small intestinal motility. The aim of the current study was to determine if 3D-MAGMA is able to detect changes in intestinal motility in people with type 2 diabetes. 18 healthy volunteers and 19 people with type 2 diabetes underwent motility testing by 3D-MAGMA. In the control group the retention time in the stomach was 33.0 [min] compared to 75.3 [min] in the diabetes group. The median time in the duodenum was 12.7 [min] compared to 8.1 [min]. The time for the first 50 cm of the jejunum was 29.9 [min] compared to 28.2 [min]. Discussion and conclusion: 3D-MAGMA is able to detect changes in intestinal motility. Its clinical value might be useful in patients with fluctuating blood glucose levels and unexplained hypoglycemic episodes.
Subject(s)
Autonomic Nervous System Diseases/diagnostic imaging , Diabetes Mellitus, Type 2/diagnostic imaging , Gastric Emptying , Gastrointestinal Motility , Gastroparesis/diagnostic imaging , Intestine, Small/diagnostic imaging , Adult , Autonomic Nervous System Diseases/etiology , Autonomic Nervous System Diseases/physiopathology , Capsules , Diabetes Mellitus, Type 2/complications , Diabetes Mellitus, Type 2/physiopathology , Female , Gastric Emptying/physiology , Gastrointestinal Motility/physiology , Gastroparesis/etiology , Gastroparesis/physiopathology , Humans , Intestine, Small/physiopathology , Magnetic Phenomena , MaleSubject(s)
IgA Vasculitis , Liver Cirrhosis/complications , Hand/pathology , Humans , Leg/pathology , Male , Middle Aged , Skin/pathologySubject(s)
Crohn Disease/diagnosis , Erythema Nodosum/diagnosis , Erythema/etiology , Leg Dermatoses/etiology , Pain/etiology , Female , HumansSubject(s)
Antineoplastic Agents/adverse effects , Bortezomib/adverse effects , Crohn Disease/therapy , Gastrointestinal Hemorrhage/etiology , Leukemia, Plasma Cell/therapy , Stem Cell Transplantation/adverse effects , Antineoplastic Agents/administration & dosage , Autografts , Bortezomib/administration & dosage , Crohn Disease/pathology , Female , Gastrointestinal Hemorrhage/pathology , Humans , Leukemia, Plasma Cell/pathology , Middle AgedABSTRACT
A case of primary Epstein-Barr virus (EBV) infection/parvovirus B19 reactivation fulfilling five of eight criteria for hemophagocytic lymphohistiocytosis (HLH) is presented. Despite two coinciding viral infections, massive splenomegaly, and fulminant hepatitis, the patient had a good clinical outcome, probably due to an early onset form of HLH with normal leukocyte count, normal natural killer (NK) cell function, and a lack of hemophagocytosis.